Brii Bio Forms $128.5 Million Collaboration for Therapeutic Hepatitis B Vaccine
publication date: Dec 6, 2018
Brii Biosciences, a China-US startup, has entered a $128.5 million agreement for China rights to an immuno-therapeutic hepatitis B vaccine from VBI Vaccines of Cambridge, MA. Brii made a $4 million upfront payment and an equity investment of $11 million in VBI, plus will pay up to $117.5 million in milestones. Brii made its debut earlier this year with $260 million in initial capital. It also announced options for China rights to four biotech infectious disease assets from Vir of San Francisco, including a hepatitis B vaccine. More details....
Stock Symbol: (NSDQ: VBIV)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.